Targeting RNA with Small Molecules to Fight HIV

  • ChemPubSoc Europe Logo
  • Author: ChemPlusChem
  • Published Date: 23 February 2020
  • Source / Publisher: ChemPlusChem/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Targeting RNA with Small Molecules to Fight HIV

Related Societies

Targeting biologically relevant RNA with drug-like small molecules is promising for the development of innovative therapeutics. There are first examples of successful clinical trials that demonstrate the potential of this approach. Targeting RNA with small molecules is possible because the 3D structure of the targets offers the possibility for specific binding. Most of the RNA ligands identified to date have been discovered by screening large compound libraries and there are only a few examples of rational design.


Maria Duca and colleagues, University Côte d’Azur, Nice, France, have screened a library of compounds to find a drug-like molecule that targets the transactivation response (TAR) RNA in the human immunodeficiency virus (HIV), or HIV‐1 TAR RNA. This RNA fragment binds to a protein called Tat (short for trans-activator of transcription) and is essential for replication of the virus. The team screened the library by measuring the compounds' affinity toward a TAR fragment (pictured).


The team found that verapamil, a commercially available calcium‐channel blocker, has a promising chemical structure for the development of new RNA ligands. The team synthesized a series of analogs of verapamil. This led to a conjugate between verapamil and an indole fragment which can inhibit the Tat/TAR interaction in vitro with a micromolar IC50 value. This is a very promising inhibition activity compared to previously reported small-molecule TAR binders.


 

 

Article Views: 858

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)published by Wiley-VCH